Targeting bone metastatic cancer: Role of the mTOR pathway

Area of Science:

• Oncology
• Molecular Biology
• Skeletal Biology

Background:

• Bone metastasis is a frequent complication of advanced solid tumors, leading to significant morbidity.
• Current treatments for bone metastases primarily manage symptoms, lacking definitive therapeutic options.
• The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth and survival and is implicated in various cancers.

Purpose of the Study:

• To review the role of mTOR pathway signaling in bone tissue.
• To summarize the effects of mTOR inhibition on bone cancer, based on existing research.
• To evaluate mTOR inhibition as a potential therapeutic strategy for bone metastatic cancer.

Main Methods:

• Literature review of studies on mTOR signaling in bone.
• Analysis of in vitro and in vivo models investigating mTOR inhibition in bone cancer.
• Synthesis of current knowledge on mTOR pathway alterations in bone malignancies.

Main Results:

• The mTOR pathway is dysregulated in pathological malignancies, including bone metastatic cancer.
• Inhibition of mTOR signaling has demonstrated anti-cancer effects in preclinical models of bone cancer.
• Understanding mTOR signaling in bone provides a basis for targeted therapeutic development.

Conclusions:

• mTOR pathway inhibition represents a promising therapeutic avenue for managing bone metastatic cancer.
• Further research into mTOR signaling in bone is warranted to develop effective treatments.
• Targeting the mTOR pathway could offer a novel strategy to combat skeletal-related events in cancer patients.